Ocugen to Participate in Upcoming September Investor and Industry Conferences

Ocugen (NASDAQ: OCGN) will highlight its modifier gene therapy platform and clinical progress at three events in September 2026.

Rhea-AI Summary

Ocugen (NASDAQ: OCGN) will highlight its modifier gene therapy platform and clinical progress at three events in September 2026. The company is participating in the Citi 2026 Biopharma Back to School Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, both as fireside chats featuring Chairman and CEO Dr. Shankar Musunuri. On September 24, Ocugen will present 12‑month randomized Phase 2 ArMaDa results for subretinal OCU410 gene therapy in geographic atrophy at The Retina Society 59th Annual Scientific Meeting, presented by Dr. Raj K. Maturi. Webcasts of the Citi and H.C. Wainwright sessions will be accessible via the Investors section of Ocugen’s website, with replays available for 30 days.

Argus Aug 25 session 7 alerts

+2.94% close to close 1.0x rel. volume Open Argus

Details

News Market Reaction – OCGN

$484.93M Market Cap

On Aug 25, the day this news came out, OCGN closed 2.94% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day.

Data tracked by StockTitan Argus for the Aug 25 session.

Key Figures

Citi conference date: September 9, 2026 H.C. Wainwright conference date: September 15, 2026 Retina Society meeting date: September 24, 2026 +5 more

Citi conference date

September 9, 2026

Citi 2026 Biopharma Back to School Conference

H.C. Wainwright conference date

September 15, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Retina Society meeting date

September 24, 2026

The Retina Society 59th Annual Scientific Meeting

Conference series

28th annual

H.C. Wainwright Global Investment Conference

Scientific meeting series

59th annual

The Retina Society Scientific Meeting

Trial phase

Phase 2

OCU410 gene therapy for geographic atrophy

Results duration

12 months

Randomized ArMaDa results presentation

Webcast replay

30 days

Replay availability following the event

Historical Context

5 past events · Latest: Aug 06

5 events

1. Aug 06

   Earnings report

   24h Move

   -3.1%

   Quarterly loss and financing activity accompanied clinical and cash runway updates

2. Jul 31

   Conference participation

   24h Move

   -2.4%

   Two August investor events were announced for the modifier gene therapy platform

3. Jul 29

   FDA designation

   24h Move

   -4.0%

   FDA granted RMAT designation for OCU410 geographic atrophy treatment

4. Jul 28

   Earnings scheduling

   24h Move

   -4.0%

   Company scheduled its second-quarter results and business-update conference call

5. Jul 13

   License term sheet

   24h Move

   -4.1%

   Binding term sheet contemplated OCU400 licensing in the MENA region

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

modifier gene therapy, subretinal, geographic atrophy, randomized phase 2

4 terms

modifier gene therapy medical

"present on its innovative modifier gene therapy platform"

Modifier gene therapy is a treatment that changes the activity of genes that influence how severe or how a disease progresses, rather than directly fixing the original faulty gene. Think of it as turning a volume knob on disease symptoms: it can make conditions milder or slow progression, which matters to investors because it can expand the number of patients who benefit, affect how quickly and cheaply a product can reach the market, and change commercial and regulatory risk and reward.

subretinal medical

"Safety and Efficacy of Subretinal OCU410 Gene Therapy"

Subretinal describes the space or actions beneath the retina, the thin light-sensing tissue at the back of the eye. It is often used to describe injections, implants, or surgical procedures that place medicine or devices directly under that layer — imagine slipping a tiny patch beneath wallpaper to treat the wall. For investors, subretinal approaches matter because they influence a treatment’s effectiveness, safety profile, surgical complexity and regulatory scrutiny, all of which affect commercial potential.

geographic atrophy medical

"OCU410 Gene Therapy for Geographic Atrophy"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

randomized phase 2 medical

"12-Month Randomized Phase 2 ArMaDa Results"

A randomized phase 2 is a mid-stage clinical study where patients are assigned by chance into different treatment groups to see whether a drug or intervention works and to find the right dose. Think of it like a structured dress rehearsal where participants are shuffled into squads so outcomes reflect the treatment, not selection choices. For investors, results narrow drug development risk and strongly affect the likelihood, timing and cost of a larger, definitive trial or commercial launch.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in September 2026.

Citi 2026 Biopharma Back to School Conference
Location: JW Marriott Essex House, New York City, NY
Date: Wednesday, September 9, 2026
Time: 3:40–4:15 p.m. ET
Format: Fireside Chat
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

H.C. Wainwright 28th Annual Global Investment Conference
Location: Lotte New York Palace, New York City, NY
Date: Tuesday, September 15, 2026
Time: 3:00–3:30 p.m. ET
Format: Fireside chat 
Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen

The Retina Society 59th Annual Scientific Meeting
Location: Fairmont Century Plaza, Los Angeles, CA
Date: September 24, 2026
Time: 3:15 p.m. PST
Format: Presentation
Title: Safety and Efficacy of Subretinal OCU410 Gene Therapy for Geographic Atrophy: 12-Month Randomized Phase 2 ArMaDa Results
Presenter: Dr. Raj K. Maturi

A webcast of the Citi and H.C. Wainwright presentations will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit Investors | Ocugen, Inc.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on LinkedIn and X.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Investors:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media:
Chris Clark
chris.clark@ocugen.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Ocugen (NASDAQ: OCGN) attend in September 2026?

Ocugen will participate in the Citi 2026 Biopharma Back to School Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. According to Ocugen, both appearances will feature fireside chats with Chairman and CEO Dr. Shankar Musunuri.

When and where is Ocugen presenting at the Citi 2026 Biopharma Back to School Conference?

Ocugen is scheduled at the Citi 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026, from 3:40–4:15 p.m. ET at JW Marriott Essex House, New York City. According to Ocugen, the format will be a fireside chat with Dr. Shankar Musunuri.

What is Ocugen’s schedule at the H.C. Wainwright 28th Annual Global Investment Conference in 2026?

Ocugen will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, from 3:00–3:30 p.m. ET at Lotte New York Palace, New York City. According to Ocugen, this session will also be a fireside chat with Dr. Shankar Musunuri.

What clinical data will Ocugen highlight at The Retina Society 59th Annual Scientific Meeting in 2026?

Ocugen will present Phase 2 ArMaDa 12‑month results on subretinal OCU410 gene therapy for geographic atrophy. According to Ocugen, this presentation, titled “Safety and Efficacy of Subretinal OCU410 Gene Therapy for Geographic Atrophy,” is scheduled for September 24, 2026, at 3:15 p.m. PST.

Will Ocugen’s September 2026 investor conference presentations be available by webcast for OCGN shareholders?

Yes. According to Ocugen, webcasts of the Citi and H.C. Wainwright fireside chats will be available on the Investors section of its website, with replay access for 30 days following each event for interested investors and stakeholders.

How can investors access Ocugen’s September 2026 conference webcasts and replays?

Investors can access Ocugen’s Citi and H.C. Wainwright presentations via the “Events and Presentation” page in the Investors section of the company’s website. According to Ocugen, replay webcasts will remain available for 30 days after each event.